News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Daily News Low Adherence to Secondary Prevention Recommendations Worldwide: INTERASPIRE Yael L. Maxwell September 23, 2024
News Conference News ESC 2024 Getting to Cholesterol Goal Early After MI Lowers Risk of Recurrent Events Michael O'Riordan September 01, 2024
News Conference News ACC 2024 NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year Yael L. Maxwell July 03, 2024
News Daily News ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal Yael L. Maxwell June 17, 2024
News Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia Michael O'Riordan May 30, 2024
News Daily News Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups Michael O'Riordan April 17, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Conference News ACC 2024 Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL Yael L. Maxwell April 09, 2024
News Conference News ACC 2024 Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI Yael L. Maxwell April 06, 2024
News Daily News High Lp(a) Levels Harmful in Patients With and Without ASCVD Michael O'Riordan February 27, 2024
News Daily News Evolocumab Reduces MACE in Patients With and Without Multivessel CAD: FOURIER Michael O'Riordan February 08, 2024